Impact of pharmacy technicians as part of an integrated health-system pharmacy team on improvement of medication access in the care of cystic fibrosis patients.
Adolescent
Child
Child, Preschool
Cystic Fibrosis
/ drug therapy
Deoxyribonuclease I
/ therapeutic use
Female
Health Services Accessibility
Humans
Infant
Infant, Newborn
Male
Pharmaceutical Services
/ organization & administration
Pharmacies
/ organization & administration
Pharmacy Technicians
Retrospective Studies
clinical pharmacy
cystic fibrosis
medications
pharmacy technician
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
25
06
2020
revised:
13
08
2020
accepted:
27
08
2020
pubmed:
3
9
2020
medline:
6
3
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Cystic fibrosis (CF) is a genetic disease requiring patients to take multiple medications per day. Multiple barriers exist affecting access and adherence. Studies have demonstrated the positive outcomes of pharmacist involvement in CF care. The purpose of this study is to characterize the impact of pharmacy technicians on medication access in the care of CF patients. A retrospective review and analysis of patient medication profiles for patients followed by the integrated pharmacy care process model was performed. Two electronic prescription pathways with pharmacy technician involvement were analyzed. One pathway using a specialty pharmacy CF pharmacy technician (SP technician) examined CF specialty medication delivery times. The other pathway examined the impact of the clinic-based CF pharmacy technician (CB technician) on the number of filling pharmacies for patients. One-hundred and fifty-three patients met inclusion criteria in the CF specialty medication delivery analysis, and 56 patients met inclusion criteria filling pharmacy analysis. The median delivery time for dornase alfa decreased from 8 days to 3 days, p < .00001. The number of patients utilizing one filling pharmacy increased from 8 (14%) to 21 (38%) (p = .005); and utilizing three filling pharmacies decreased from 14 (25%) to 1 (2%) (p = .003). The study demonstrated that pharmacy technicians as part of an integrated health-system pharmacy care process model improve medication access in the care of CF patients.
Sections du résumé
BACKGROUND
Cystic fibrosis (CF) is a genetic disease requiring patients to take multiple medications per day. Multiple barriers exist affecting access and adherence. Studies have demonstrated the positive outcomes of pharmacist involvement in CF care. The purpose of this study is to characterize the impact of pharmacy technicians on medication access in the care of CF patients.
METHODS
A retrospective review and analysis of patient medication profiles for patients followed by the integrated pharmacy care process model was performed. Two electronic prescription pathways with pharmacy technician involvement were analyzed. One pathway using a specialty pharmacy CF pharmacy technician (SP technician) examined CF specialty medication delivery times. The other pathway examined the impact of the clinic-based CF pharmacy technician (CB technician) on the number of filling pharmacies for patients.
RESULTS
One-hundred and fifty-three patients met inclusion criteria in the CF specialty medication delivery analysis, and 56 patients met inclusion criteria filling pharmacy analysis. The median delivery time for dornase alfa decreased from 8 days to 3 days, p < .00001. The number of patients utilizing one filling pharmacy increased from 8 (14%) to 21 (38%) (p = .005); and utilizing three filling pharmacies decreased from 14 (25%) to 1 (2%) (p = .003).
CONCLUSION
The study demonstrated that pharmacy technicians as part of an integrated health-system pharmacy care process model improve medication access in the care of CF patients.
Substances chimiques
Deoxyribonuclease I
EC 3.1.21.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3351-3357Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142-151.
Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med. 2013;19(6):687-691.
George M, Rand-Giovannetti D, Eakin MN, Borrelli B, Zettler M, Riekert KA. Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros. 2010;9(6):425-432.
Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177-185.
Bregnballe V, Schiøtz PO, Boisen KA, Pressler T, Thastum M. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence. 2011;5:507-515.
Orenstein DM, Abood RN. Cost(s) of caring for patients with cystic fibrosis. Curr Opin Pediatr. 2018;30(3):393-398.
LLC., B.S. 2017. https://cysticfibrosisnewstoday.com/2017/11/16/cff-helps-cystic-fibrosis-patients-navigate-the-confusing-maze-of-health-insurance/. Accessed May 16, 2020.
Cystic Fibrosis Foundation. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009;155(6 Supp):S106-S116.
Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 Supp):1S-39S.
Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018;53(12):1611-1618.
Cystic Fibrosis Foundation. Your CF care team. https://www.cff.org/Care/Your-CF-Care-Team/. Accessed May 16, 2020.
Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4(1):7-26.
Cystic Fibrosis Trust. Standards for the clinical care of children and adults with cystic fibrosis in the UK. 2011.
Cystic Fibrosis Foundation. Cystic fibrosis standards of care. Australia. 2008.
Cystic Fibrosis Trust. Pharmacy standards in cystic fibrosis care. 2011.
Sterner-Allison JL. Management of adolescent and adult inpatients with cystic fibrosis. Am J Health Syst Pharm. 1999;56(2):158-60.
Cies JJ, Varlotta L. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients. Pediatr Pulmonol. 2013;48(12):1190-1194.
Zobell JT, Schwab E, Collingridge DS, Ball C, Nohavec R, Asfour F. Impact of pharmacy services on cystic fibrosis medication adherence. Pediatr Pulmonol. 2017;52(8):1006-1012.
Zobell JT, Collingridge DS, Asfour F. Impact of pharmacy services on cystic fibrosis medication adherence: update. Pediatr Pulmonol. 2018;53(6):694-695.
Wright BA, Singh SB, Schultz JL, et al. Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center. Pediatr Pulmonol. 2019;54(10):1591-1595.
Young DC, Autry E, Zobell JT, et al. Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. Pediatr Pulmonol. 2019;54(8):1216-1224.
Social Science Statistics. https://www.socscistatistics.com/tests/mannwhitney/. Accessed May 18, 2020.
Social Science Statistics. https://www.socscistatistics.com/tests/chisquare2/. Accessed August 13, 2020.